Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
GF Watts, SS Gidding, P Mata, J Pang… - Nature Reviews …, 2020 - nature.com
Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …
Lipid management across Europe in the real-world setting: a rapid evidence review
V Barrios, J Soronen, AM Carter… - … Medical Research and …, 2021 - Taylor & Francis
Objective To provide a contemporary overview of recent real-world lipid-lowering therapy
(LLT) practices and outcomes in patients with hypercholesterolemia/dyslipidemia at …
(LLT) practices and outcomes in patients with hypercholesterolemia/dyslipidemia at …
Drug screening in human PSC-cardiac organoids identifies pro-proliferative compounds acting via the mevalonate pathway
We have previously developed a high-throughput bioengineered human cardiac organoid
(hCO) platform, which provides functional contractile tissue with biological properties similar …
(hCO) platform, which provides functional contractile tissue with biological properties similar …
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Immediate and aggressive lipid lowering therapies after acute coronary syndromes (ACS)
and percutaneous coronary interventions (PCI) are supported by the ESC/EAS dyslipidemia …
and percutaneous coronary interventions (PCI) are supported by the ESC/EAS dyslipidemia …
Polysaccharide MCP extracted from Morchella esculenta reduces atherosclerosis in LDLR-deficient mice
D Wang, Z Yin, L Ma, L Han, Y Chen, W Pan, K Gong… - Food & function, 2021 - pubs.rsc.org
The pharmaceutical application of fungal polysaccharides has been extensively studied
based on their multiple biological activities. However, the effect of Morchella esculenta …
based on their multiple biological activities. However, the effect of Morchella esculenta …
[HTML][HTML] PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
J Vicente-Valor, X García-González… - Biomedicine & …, 2022 - Elsevier
Introduction Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have emerged
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
as a therapeutic option for patients with hypercholesterolemia who do not attain low-density …
PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization
Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …
PCSK9 inhibitors' new users: analysis of prescription patterns and patients' characteristics from an Italian real-world study
C Piccinni, IC Antonazzo, AP Maggioni… - Clinical Drug …, 2020 - Springer
Abstract Background and Objective Cardiovascular (CV) diseases represent a major cause
of death and severe medical condition worldwide. Different therapeutic options are available …
of death and severe medical condition worldwide. Different therapeutic options are available …
Lipid‐lowering therapy with PCSK 9‐inhibitors in the real‐world setting: Two‐year experience of a regional lipid clinic
Aim PCSK 9 inhibitors (PCSK 9i) effectively lower cholesterol levels in randomized trials with
reduction in cardiovascular outcomes and favorable safety profile. However, the access to …
reduction in cardiovascular outcomes and favorable safety profile. However, the access to …
[HTML][HTML] PCSK9 inhibitors in clinical practice: novel directions and new experiences
LS Rallidis, I Skoumas, EN Liberopoulos… - Hellenic Journal of …, 2020 - Elsevier
Background In randomized clinical trials, proprotein convertase subtilisin/kexin type 9
inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a …
inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a …